PubMed

Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.

Takeda AL, Colquitt J, Clegg AJ, Jones J.

Br J Ophthalmol. 2007 Sep;91(9):1177-82. Epub 2007 May 2. Review.PMID: 17475698 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.PMID: 18462575 [PubMed - indexed for MEDLINE]Related articlesFree article

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.

Vedula SS, Krzystolik MG.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005139. Review.PMID: 18425911 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B.

Ophthalmology. 2006 Jun;113(6):992-1001.e6. Epub 2006 Apr 27.PMID: 16647134 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.PMID: 18035187 [PubMed - indexed for MEDLINE]Related articles

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M.

Ophthalmology. 2006 Sep;113(9):1508.e1-25. Epub 2006 Jul 7.PMID: 16828500 [PubMed - indexed for MEDLINE]Related articles

Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.

Farah SE.

Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug;39(4):294-8.PMID: 18717434 [PubMed - indexed for MEDLINE]Related articles

[New drugs; pegaptanib and ranibizumab]

van Bronswijk H, Dubois EA, van Meurs JC, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Jan 12;152(2):82-4. Review. Dutch. PMID: 18265796 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.PMID: 18035208 [PubMed - indexed for MEDLINE]Related articles

Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.

Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.

Ophthalmology. 2008 Feb;115(2):347-354.e2. Epub 2007 Jul 12.PMID: 17628685 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.

Am J Ophthalmol. 2007 Dec;144(6):850-857. Epub 2007 Oct 22.PMID: 17949673 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib for neovascular age-related macular degeneration.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.

N Engl J Med. 2004 Dec 30;351(27):2805-16.PMID: 15625332 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.

Quiram PA, Hassan TS, Williams GA.

Retina. 2007 Sep;27(7):851-6.PMID: 17891008 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51.PMID: 19167602 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Schiller DS.

Clin Ther. 2006 Jan;28(1):36-44. Review.PMID: 16490578 [PubMed - indexed for MEDLINE]Related articles

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group.

Ophthalmology. 2007 Oct;114(10):1868-75. Epub 2007 Jul 12.PMID: 17628683 [PubMed - indexed for MEDLINE]Related articles

Pegaptanib for neovascular age-related macular degeneration.

Maberley D.

Issues Emerg Health Technol. 2005 Dec;(76):1-4.PMID: 16544440 [PubMed - indexed for MEDLINE]Related articles

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group.

Ophthalmology. 2007 Feb;114(2):246-52.PMID: 17270674 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group.

Arch Ophthalmol. 2006 Nov;124(11):1532-42. Erratum in: Arch Ophthalmol. 2007 Jan;125(1):138. PMID: 17101999 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles